title: A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic.
abstract: Animal studies suggest that kappa opioid receptor antagonists (KORAn) potentially could treat a wide variety of addictive and depressive disorders. We assessed the KORAn JDTic for safety, tolerability, and pharmacokinetics in a double-blind, placebo-controlled, randomized trial evaluating single oral doses in healthy adult males. Predose and postdose safety assessments included orthostatic vital signs; 6-lead continuous telemetry monitoring (approximately 16 h predose to 24 h postdose); 12-lead electrocardiograms (ECGs); clinical chemistry, hematology, coagulation, and urinalysis; psychomotor functioning (using the Wayne Saccadic Fixator (WSF)); and adverse events. As a potential indicator of JDTic effects on affect, the POMS Standard instrument was administered predose and daily postdose Days 1-6. At 1 mg, 2 of the 6 JDTic (and 0/6 placebo) subjects experienced a single, asymptomatic event of multiple beats of nonsustained ventricular tachycardia (NSVT). Their events were temporally similar with respect to time postdose (and the postdose timing of an NSVT event in a monkey). These events triggered a study stopping rule. No differences were observed between the placebo and JDTic subjects with respect to clinical chemistry, hematology, coagulation, urinalysis, orthostatic vital signs, WSF, or 12-lead ECG parameters. Plasma JDTic levels were below the lower limit of quantitation (0.1 nM) in all subjects. There were no significant differences in POMS scores between the placebo and JDTic groups. Although the evidence is circumstantial, it suggests that NSVT is a potential JDTic toxicity in humans. Given the therapeutic potential of KORAn, further investigation is needed to determine whether a significant JDTic human cardiac effect indeed exists, and if so, whether it is specific to JDTic or represents a KORAn class effect.
authors: RTI Health Solutions, Research Triangle Park, NC, USA.
authors: Jeffrey J
authors: JJ
authors: Buda
authors: RTI International, Research Triangle Park, NC, USA.
authors: F I
authors: FI
authors: Carroll
authors: Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.
authors: Thomas R
authors: TR
authors: Kosten
authors: Celerion, Tempe, AZ, USA.
authors: Dennis
authors: D
authors: Swearingen
authors: RTI International, Research Triangle Park, NC, USA.
authors: Bradford B
authors: BB
authors: Walters
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004562:Electrocardiography; D005215:Fasting / Q000652:urine; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000097:blood / Q000493:pharmacokinetics*; D017473:Receptors, Opioid, kappa / Q000037:antagonists & inhibitors*; D017180:Tachycardia, Ventricular / Q000139:chemically induced*; D044005:Tetrahydroisoquinolines / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors; D055815:Young Adult
chemical_list: C433814:7-hydroxy-N-(1-((4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide; D010880:Piperidines; D017473:Receptors, Opioid, kappa; D044005:Tetrahydroisoquinolines
references: Mol Pharmacol. 2011 Nov;80(5):920-9
references: 21832171
references: J Med Chem. 2013 Mar 28;56(6):2178-95
references: 23360448
references: J Mol Cell Cardiol. 2013 Jul;60:142-50
references: 23608604
references: ChemMedChem. 2014 Aug;9(8):1638-54
references: 24981721
references: J Clin Pharmacol. 2014 Sep;54(9):968-78
references: 24619932
references: Heart Vessels. 2014 Nov;29(6):855-63
references: 24390763
references: J Clin Forensic Med. 2005 Aug;12(4):218-9
references: 16054011
references: Shock. 2005 Nov;24(5):470-5
references: 16247334
references: Anesth Analg. 2006 Oct;103(4):822-32
references: 17000788
references: J Biol Chem. 2007 Oct 12;282(41):29803-11
references: 17702750
references: Bull Exp Biol Med. 2007 Feb;143(2):187-90
references: 17970197
references: Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1444-51
references: 18203844
references: Am J Physiol Heart Circ Physiol. 2001 Jul;281(1):H40-7
references: 11406466
references: Am J Physiol Heart Circ Physiol. 2001 Aug;281(2):H669-78
references: 11454571
references: Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H2091-9
references: 12543635
references: J Med Chem. 2003 Jul 3;46(14):3127-37
references: 12825951
references: Eur J Pharmacol. 2003 Jul 25;473(2-3):97-103
references: 12892826
references: J Cardiovasc Pharmacol. 2004 Mar;43(3):410-5
references: 15076225
references: Am J Cardiol. 1969 Nov;24(5):629-50
references: 5347937
references: Am J Cardiol. 1977 Mar;39(3):390-5
references: 65912
references: Lancet. 1976 Sep 4;1(7984):508-12
references: 74472
references: Eur Heart J. 1982 Dec;3(6):493-503
references: 7160388
references: Circ Res. 1992 Jan;70(1):66-81
references: 1309318
references: Am J Vet Res. 1993 Feb;54(2):327-32
references: 8430943
references: Clin Sci (Lond). 1993 Jul;85(1):1-4
references: 7908617
references: Neuropeptides. 1995 Aug;29(2):115-9
references: 7477762
references: J Mol Cell Cardiol. 1998 Oct;30(10):2103-10
references: 9799662
references: J Am Coll Cardiol. 1999 Jun;33(7):1863-9
references: 10362186
references: J Mol Cell Cardiol. 1999 Oct;31(10):1809-19
references: 10525419
references: Pacing Clin Electrophysiol. 2005 Jan;28 Suppl 1:S275-9
references: 15683515
references: Arch Med Res. 2008 Jul;39(5):483-8
references: 18514092
references: Am Heart J. 2010 May;159(5):716-29
references: 20435178
references: Psychopharmacology (Berl). 2010 Jun;210(2):137-47
references: 20401607
references: Mol Cell Biochem. 2010 Dec;345(1-2):231-40
references: 20730476
references: Toxicol Sci. 2011 Sep;123(1):281-9
references: 21693436
references: J Biol Chem. 2011 Oct 21;286(42):36331-9
references: 21873422
references: Am J Med Sci. 2013 Feb;345(2):129-35
references: 22735633
references: Drug Alcohol Depend. 2012 Aug 1;124(3):223-8
references: 22356890